Analysts See $-0.03 EPS for Oncolytics Biotech Inc. (ONC), Tesoro Has 1.02 Sentiment

July 28, 2017 - By Dolores Ford

Tesoro Corporation is an independent petroleum refining, logistics and marketing company. he Company operates through three divisions. The company has market cap of $15.65 billion. The Refining operating segment refines crude oil and other feedstocks into transportation fuels, such as gasoline and gasoline blendstocks, jet fuel and diesel fuel, as well as other products, including heavy fuel oils, liquefied petroleum gas and petroleum coke for sale in bulk markets to a range of clients within its markets. It has a 16.35 P/E ratio. The TLLP segment comprises Tesoro Logistics LP’s (TLLP) assets and operations, and includes certain natural gas and crude oil gathering assets, natural gas and natural gas liquids (NGLs) processing assets, and crude oil and refined products terminaling, transportation and storage assets acquired from Tesoro and third parties.

Analysts expect Oncolytics Biotech Inc. (TSE:ONC) to report $-0.03 EPS on August, 3.They anticipate $0.01 EPS change or 50.00% from last quarter’s $-0.02 EPS. After having $-0.03 EPS previously, Oncolytics Biotech Inc.’s analysts see 0.00% EPS growth. It closed at $0.51 lastly. It is down 0.00% since July 28, 2016 and is . It has underperformed by 16.70% the S&P500.

It closed at $97.7 lastly. It is down 7.01% since July 28, 2016 and is uptrending. It has underperformed by 9.69% the S&P500.

Hound Partners Llc holds 9.19% of its portfolio in Tesoro Corporation for 4.35 million shares. Slate Path Capital Lp owns 1.82 million shares or 4.83% of their US portfolio. Moreover, Steadfast Advisors Lp has 4.59% invested in the company for 107,126 shares. The New York-based Steadfast Capital Management Lp has invested 4.56% in the stock. Point72 Asset Management L.P., a Connecticut-based fund reported 3.42 million shares.

Ratings analysis reveals 100% of Tesoro’s analysts are positive. Out of 4 Wall Street analysts rating Tesoro, 4 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. TSO was included in 4 notes of analysts from August 23, 2016. The stock has “Overweight” rating by JP Morgan on Thursday, February 2. The firm has “Outperform” rating given on Monday, December 12 by Wells Fargo. Credit Suisse upgraded Tesoro Corporation (NYSE:TSO) on Tuesday, October 11 to “Outperform” rating. The company was initiated on Tuesday, August 23 by Jefferies.

Since January 1, 0001, it had 2 insider buys, and 1 sale for $48,584 activity.

Analysts await Tesoro Corporation (NYSE:TSO) to report earnings on August, 8 after the close. They expect $1.52 EPS, down 56.20% or $1.95 from last year’s $3.47 per share. TSO’s profit will be $243.48 million for 16.07 P/E if the $1.52 EPS becomes a reality. After $0.52 actual EPS reported by Tesoro Corporation for the previous quarter, Wall Street now forecasts 192.31% EPS growth.

Oncolytics Biotech Inc. is a development-stage company. The company has market cap of $62.14 million. The Firm is focused on the development of REOLYSIN, its cancer therapeutic. It currently has negative earnings. The Company’s clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials.